BRPI0511753A - formulação de irinotecano e respectiva composição farmacêutica - Google Patents
formulação de irinotecano e respectiva composição farmacêuticaInfo
- Publication number
- BRPI0511753A BRPI0511753A BRPI0511753-4A BRPI0511753A BRPI0511753A BR PI0511753 A BRPI0511753 A BR PI0511753A BR PI0511753 A BRPI0511753 A BR PI0511753A BR PI0511753 A BRPI0511753 A BR PI0511753A
- Authority
- BR
- Brazil
- Prior art keywords
- irinotecan
- formulation
- mol
- liposome
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
FORMULAçãO DE IRINOTECANO E RESPECTIVA COMPOSIçãO FARMACêUTICA. A presente invenção refere-se a uma formulação de irinotecano capaz de suportar o irinotecano e/ou um sal do mesmo em um veículo de vesícula fechada, em uma alta concentração, e existindo no sangue por um período longo de tempo pela retentividade dramaticamente aperfeiçoada no sangue, comparada a uma formulação de lipossomo de irinotecano convencionalmente conhecida. Ou seja, uma formulação de irinotecano que inclui uma vesícula fechada formada por uma membrana lipídica, em que o irinotecano e/ou um sal do mesmo é encapsulado em uma concentração de pelo menos 0,07 mol/mol (mol de fármaco/mol de lipídios totais da membrana). Há um gradiente iónico entre uma fase aquosa interna e uma fase aquosa externa na formulação de irinotecano. A vesícula fechada é preferivelmente o lipossomo, em que somente a superfície externa do lipossomo é preferivelmente modificada com um agente modificador da superfície contendo um polímero hidrofílico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004163742 | 2004-06-01 | ||
PCT/JP2005/009953 WO2005117878A1 (ja) | 2004-06-01 | 2005-05-31 | イリノテカン製剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0511753A true BRPI0511753A (pt) | 2008-01-02 |
Family
ID=35462721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0511753-4A BRPI0511753A (pt) | 2004-06-01 | 2005-05-31 | formulação de irinotecano e respectiva composição farmacêutica |
Country Status (24)
Country | Link |
---|---|
US (1) | US7846473B2 (pt) |
EP (1) | EP1752150B1 (pt) |
JP (1) | JP4885715B2 (pt) |
KR (1) | KR100889139B1 (pt) |
CN (1) | CN1960729B (pt) |
AP (1) | AP2255A (pt) |
AR (1) | AR049137A1 (pt) |
AU (1) | AU2005249314B2 (pt) |
BR (1) | BRPI0511753A (pt) |
CA (1) | CA2567857C (pt) |
CR (1) | CR8768A (pt) |
EA (1) | EA011612B1 (pt) |
EC (1) | ECSP067041A (pt) |
ES (1) | ES2594621T3 (pt) |
GE (1) | GEP20094620B (pt) |
IL (1) | IL179558A0 (pt) |
MX (1) | MXPA06013874A (pt) |
NO (1) | NO20066074L (pt) |
NZ (1) | NZ551748A (pt) |
TN (1) | TNSN06395A1 (pt) |
TW (1) | TWI362931B (pt) |
UA (1) | UA85099C2 (pt) |
WO (1) | WO2005117878A1 (pt) |
ZA (1) | ZA200610204B (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1746976T3 (pl) | 2004-05-03 | 2017-09-29 | Merrimack Pharmaceuticals, Inc. | Liposomy przydatne w systemie podawania leków |
US20090196917A1 (en) * | 2008-02-01 | 2009-08-06 | University Of Kentucky Research Foundation | Liposomal Formulations of Hydrophobic Lactone Drugs in the Presence of Metal Ions |
CA2724408A1 (en) * | 2008-05-19 | 2009-11-26 | The University Of North Carolina At Chapel Hill | Methods and compositions comprising novel cationic lipids |
WO2010058840A1 (ja) * | 2008-11-20 | 2010-05-27 | テルモ株式会社 | リポソームからの薬物放出手段および放出性評価法 |
CN103120645B (zh) * | 2009-12-03 | 2015-03-11 | 江苏恒瑞医药股份有限公司 | 伊立替康或盐酸伊立替康脂质体及其制备方法 |
EP2508170B1 (en) * | 2009-12-03 | 2015-07-29 | Jiangsu Hengrui Medicine Co., Ltd. | Liposome of irinotecan or its hydrochloride and preparation method thereof |
US10980798B2 (en) | 2011-11-03 | 2021-04-20 | Taiwan Liposome Company, Ltd. | Pharmaceutical compositions of hydrophobic camptothecin derivatives |
AU2012332176B2 (en) | 2011-11-03 | 2016-03-10 | Tlc Biopharmaceuticals, Inc. | Pharmaceutical compositions of hydrophobic camptothecin derivatives |
KR101842279B1 (ko) * | 2012-03-29 | 2018-03-26 | 우석대학교 산학협력단 | 이리노테칸의 안정성증진을 위한 주사제용 조성물 |
AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
EA023079B1 (ru) * | 2012-12-24 | 2016-04-29 | Общество С Ограниченной Ответственностью "Технология Лекарств" | Способ получения липосомальной формы иринотекана (варианты) |
CN104906586A (zh) * | 2014-03-10 | 2015-09-16 | 中国科学院上海药物研究所 | 一种盐酸伊立替康复合磷脂组合物、制备方法及其应用 |
CN105796495B (zh) * | 2014-12-29 | 2020-10-23 | 南京绿叶制药有限公司 | 一种盐酸伊立替康脂质体药物组合物及其制备方法 |
CN105982857B (zh) * | 2015-02-09 | 2019-03-08 | 湖南科伦药物研究有限公司 | 一种盐酸伊立替康脂质体组合物及其制备方法 |
ES2589320B2 (es) * | 2015-04-14 | 2017-06-01 | Universidad Politécnica de Madrid | Sistema de compartimentación de espacios con membranas enrollables |
US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
KR101646181B1 (ko) * | 2015-08-18 | 2016-08-05 | 한양대학교 에리카산학협력단 | 이리노테칸 함유 이중역상 온도감응성 수용성 겔 조성물 |
SI3337467T1 (sl) | 2015-08-20 | 2021-03-31 | Ipsen Biopharm Ltd. Ash Road | Kombinacijska terapija, ki vsebuje liposomski irinotekan in zaviralec PARP za zdravljenje raka |
EP3791876A1 (en) | 2015-08-21 | 2021-03-17 | Ipsen Biopharm Ltd. | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin |
SG10201912568PA (en) | 2015-10-16 | 2020-02-27 | Ipsen Biopharm Ltd | Stabilizing camptothecin pharmaceutical compositions |
SG11201903615WA (en) * | 2016-11-02 | 2019-05-30 | Ipsen Biopharm Ltd | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
KR102066402B1 (ko) * | 2017-12-22 | 2020-01-15 | 대화제약 주식회사 | 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물 |
CN109260155B (zh) | 2018-11-05 | 2021-04-06 | 杭州高田生物医药有限公司 | 伊立替康脂质体制剂及其制备与应用 |
KR102185475B1 (ko) * | 2019-06-20 | 2020-12-02 | 대화제약 주식회사 | 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물 |
CA3231432A1 (en) * | 2021-10-15 | 2023-04-20 | Tianyi Ke | Composition containing antitumor drug, and preparation method therefor and use thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
IL91664A (en) * | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
WO1995008986A1 (en) | 1993-09-27 | 1995-04-06 | Smithkline Beecham Corporation | Camptothecin formulations |
US5827533A (en) | 1997-02-06 | 1998-10-27 | Duke University | Liposomes containing active agents aggregated with lipid surfactants |
US6090407A (en) | 1997-09-23 | 2000-07-18 | Research Development Foundation | Small particle liposome aerosols for delivery of anti-cancer drugs |
DK1121102T3 (da) * | 1998-09-16 | 2003-08-11 | Alza Corp | Liposomindesluttede topoisomeraseinhibitorer |
JP2001064158A (ja) * | 1999-06-25 | 2001-03-13 | Terumo Corp | リポソーム |
DE60042159D1 (en) * | 1999-06-25 | 2009-06-18 | Terumo Corp | Liposome |
US6352996B1 (en) | 1999-08-03 | 2002-03-05 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
MXPA02012817A (es) * | 2000-06-30 | 2004-07-30 | Inex Pharmaceuticals Inc | Drogas antineoplasicas liposomales y uso de las mismas. |
EP1432402B1 (en) | 2001-10-03 | 2006-11-22 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
WO2003028697A2 (en) * | 2001-10-03 | 2003-04-10 | Celator Technologies Inc. | Liposome loading with metal ions |
EP1443900B1 (en) * | 2001-11-13 | 2012-05-23 | Celator Pharmaceuticals, Inc. | Lipid carrier compositions with enhanced blood stability |
ATE373466T1 (de) | 2001-11-13 | 2007-10-15 | Celator Pharmaceuticals Inc | Lipidträgerzusammensetzungen und verfahren zur verbesserten wirkstoffzurückhaltung |
CA2527130A1 (en) * | 2003-04-02 | 2004-10-14 | Paul Tardi | Pharmaceutical compositions containing active agents having a lactone group and transition metal ions |
PL1746976T3 (pl) * | 2004-05-03 | 2017-09-29 | Merrimack Pharmaceuticals, Inc. | Liposomy przydatne w systemie podawania leków |
US8658203B2 (en) * | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
-
2005
- 2005-05-31 BR BRPI0511753-4A patent/BRPI0511753A/pt not_active IP Right Cessation
- 2005-05-31 JP JP2006514098A patent/JP4885715B2/ja active Active
- 2005-05-31 CA CA002567857A patent/CA2567857C/en not_active Expired - Fee Related
- 2005-05-31 ES ES05745848.1T patent/ES2594621T3/es active Active
- 2005-05-31 KR KR1020067025238A patent/KR100889139B1/ko active IP Right Grant
- 2005-05-31 US US11/597,435 patent/US7846473B2/en active Active
- 2005-05-31 EP EP05745848.1A patent/EP1752150B1/en active Active
- 2005-05-31 CN CN2005800176008A patent/CN1960729B/zh not_active Expired - Fee Related
- 2005-05-31 UA UAA200614105A patent/UA85099C2/ru unknown
- 2005-05-31 AP AP2006003837A patent/AP2255A/xx active
- 2005-05-31 WO PCT/JP2005/009953 patent/WO2005117878A1/ja active Application Filing
- 2005-05-31 MX MXPA06013874A patent/MXPA06013874A/es not_active Application Discontinuation
- 2005-05-31 GE GEAP20059794A patent/GEP20094620B/en unknown
- 2005-05-31 NZ NZ551748A patent/NZ551748A/en unknown
- 2005-05-31 EA EA200602246A patent/EA011612B1/ru not_active IP Right Cessation
- 2005-05-31 AU AU2005249314A patent/AU2005249314B2/en not_active Ceased
- 2005-06-01 TW TW094118012A patent/TWI362931B/zh not_active IP Right Cessation
- 2005-06-01 AR ARP050102246A patent/AR049137A1/es unknown
-
2006
- 2006-11-23 CR CR8768A patent/CR8768A/es unknown
- 2006-11-23 IL IL179558A patent/IL179558A0/en unknown
- 2006-11-29 EC EC2006007041A patent/ECSP067041A/es unknown
- 2006-11-30 TN TNP2006000395A patent/TNSN06395A1/en unknown
- 2006-12-06 ZA ZA200610204A patent/ZA200610204B/xx unknown
- 2006-12-29 NO NO20066074A patent/NO20066074L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0511753A (pt) | formulação de irinotecano e respectiva composição farmacêutica | |
Sundin et al. | Gentamicin inhibits renal protein and phospholipid metabolism in rats: implications involving intracellular trafficking | |
Grijalba et al. | Ca2+-induced increased lipid packing and domain formation in submitochondrial particles. A possible early step in the mechanism of Ca2+-stimulated generation of reactive oxygen species by the respiratory chain | |
Stefanovic et al. | α‐Synuclein oligomers distinctively permeabilize complex model membranes | |
US4921644A (en) | Mucin directed lipsome | |
CN101039689B (zh) | 用于上皮相关病症的局部组合物和方法 | |
Pata et al. | Membrane solubilization by detergent: resistance conferred by thickness | |
Alarcón et al. | Ion channel formation by Alzheimer's disease amyloid β-peptide (Aβ40) in unilamellar liposomes is determined by anionic phospholipids | |
Jaremko et al. | Accelerated hemolysis and neurotoxicity in neuron‐glia‐blood clot co‐cultures | |
Ježek et al. | A structure–activity study of fatty acid interaction with mitochondrial uncoupling protein | |
Dong et al. | Protective effect of HIF-1α against hippocampal apoptosis and cognitive dysfunction in an experimental rat model of subarachnoid hemorrhage | |
Liu et al. | Antimicrobial tissue concentrations | |
Mingeot‐Leclercq et al. | Molecular parameters involved in aminoglycoside nephrotoxicity | |
Ostroumova et al. | The interaction of dipole modifiers with amphotericin-ergosterol complexes. Effects of phospholipid and sphingolipid membrane composition | |
BRPI0416650A (pt) | composição de lipossoma estável para a aplicação de um agente farmacêutico, composição de lipossoma estéril e estável para a aplicação de um agente farmacêutico método para a produção de uma composição de lipossoma estável para a aplicação de um agente farmacêutico, composição farmacêutica, uso de uma composição de lipossoma, dispositivo para conter uma composição de lipossoma estável, kit para a aplicação de um agente farmacêutico a um paciente, método para aumentar a estabilidade de composições de lipossomas, método para a identificação de uma composição de lipossoma estável na fase, composição de lipossoma e composição de lipossoma estável na fase | |
Yildiz et al. | The protective role of fosfomycin in lung injury due to oxidative stress and inflammation caused by sepsis | |
Romero et al. | Formation of two different types of ion channels by amphotericin B in human erythrocyte membranes | |
Fabrizio et al. | In vitro permeation of desmopressin across rabbit nasal mucosa from liquid nasal sprays: the enhancing effect of potassium sorbate | |
Fait et al. | Volume expansion of erythrocytes is not the only mechanism responsible for the protection by arginine-based surfactants against hypotonic hemolysis | |
Tuneva et al. | Effect of NMDA on production of reactive oxygen species by human lymphocytes | |
Steinberg et al. | Sustained‐release delivery systems of triclosan for treatment of Streptococcus mutans biofilm | |
Shimizu et al. | pH switching that crosses over the isoelectric point (pI) can improve the entrapment of proteins within giant liposomes by enhancing protein–membrane interaction | |
Tjong et al. | Role of glycosphingolipid conformational change in membrane pore forming activity of cobra cardiotoxin | |
Bartkowiak et al. | Study of mucin interaction with model phospholipid membrane at the air–water interface | |
Sadzuka et al. | Effects of intraperitoneal administration of liposomes and methods of preparing liposomes for local therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DA 8A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013. |